Ribociclib Improves Survival in Advanced Breast Cancer
WEBOct 6, 2021 · Women with metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their initial treatment lived approximately 1 year longer overall than women treated with letrozole only, updated results from the MONALEESA-2 …
FDA Approves Ribociclib for Early Breast Cancer Treatment With …
WEBSep 17, 2024 · The FDA approved ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive (HR+), HER2-negative (HER2–) stage II and III early breast ...
FDA approval of new drug regimen helps reduce risk of breast …
WEBSep 17, 2024 · Ribociclib is a cyclin-dependent kinase inhibitor that works by blocking the activity of cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast ...
WEBMar 9, 2022 · In our trial, the addition of ribociclib significantly prolonged overall survival as compared with letrozole alone when given to postmenopausal patients with HR-positive, HER2-negative advanced...
FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer
WEBSep 17, 2024 · The FDA has approved adjuvant ribociclib (Kisqali) plus an aromatase inhibitor (AI) for the treatment of patients with hormone receptor–positive, HER2-negative stage II and III early breast ...
Ribociclib plus Endocrine Therapy in Early Breast Cancer
WEBMar 20, 2024 · The 3-year regimen of ribociclib at a 400-mg starting dose plus an NSAI was not associated with any new safety signals. Conclusions. Ribociclib plus an NSAI significantly improved invasive...
Ribociclib Combo Approved in HR+/HER2- Stage II-III Early Breast …
WEBSep 17, 2024 · The FDA has approved ribociclib (Kisqali) plus an aromatase inhibitor as adjuvant treatment for patients with hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer at high risk of recurrence, according to a …
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
WEB5 days ago · The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human...
FDA approves first cancer drug through new oncology review pilot …
WEBThe U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone...
Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as …
WEBApr 11, 2024 · Ribociclib is a cyclin-dependent kinase 4/6 inhibitor whose efficacy and safety have been proven through a robust series of phase III randomized clinical trials (RCTs) called MONALEESA. Knowledge generated by the BrasiLEEira study shows that progression-free survival at 12 months was 77.6% among included patients, a rate …